ACE and myotonic dystrophy type 1: The assumption that cardiac dysfunction can be prevented (or at least attenuated) in DM1 patients has led to the belief that angiotensin converting enzyme-inhibithors (ACE-I) should be initiated at an early stage of the disease, rather than delayed until ventricular dilatation or systolic dysfunction become apparent.